# OnCo record mesoblast (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/mesoblast/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "mesoblast" ;
  schema:name "Mesoblast"@en ;
  schema:alternateName "Mesoblast, Inc."@en, "Mesoblast Limited"@en ;
  schema:description "Mesoblast is an Australian cell therapy company whose remestemcel-L became in December 2024 the first mesenchymal stromal cell therapy approved by the FDA, for children with steroid-refractory acute graft-versus-host disease."@en ;
  schema:url <https://onco.cc/companies/mesoblast/>, <https://www.mesoblast.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Mesoblast> ;
  owl:sameAs <http://www.wikidata.org/entity/Q25326524> ;
  schema:citation <https://www.fda.gov/news-events/press-announcements/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host> ;
  onco:tag "fda-oce-applicant" ;
  schema:addressCountry "AU" ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:drugs <https://onco.cc/drugs/remestemcel-l/> .